Key Highlights
- CelLBxHealth plc (LSE:CLBX), formerly ANGLE, expects 2026 revenue of at least £2.1 million, about 50% growth on 2025.
- Second-quarter revenue doubled and the cost base has been cut sharply after restructuring.
- A peer-reviewed study published on 3 August 2026 showed Parsortix can detect antibody-drug conjugate targets on circulating tumour cells.
- The company signed an additional statement of work worth about $65,000 with a US pharmaceutical customer.
- Funding beyond the second quarter of 2027 remains a key question for investors.
Why CelLBxHealth Is in Focus Today
CelLBxHealth plc (LSE:CLBX) is attracting attention on AIM on 20 October 2026 because its third quarter has just ended, and the company is under pressure to show that commercial momentum is building fast enough to secure its future. Investors want evidence of further pharma contracts, progress toward its revenue guidance and clarity on cash runway.
Company Background
CelLBxHealth, previously known as ANGLE plc, is based in Guildford, UK, with US operations in Plymouth Meeting, Pennsylvania. It describes itself as a circulating tumour cell intelligence company. Its patented Parsortix platform captures and harvests rare cancer cells from blood samples without relying on surface markers, preserving intact cells for imaging, proteomic and genomic analysis. Parsortix PC1 was the first device cleared by the FDA for capturing and harvesting intact circulating tumour cells from metastatic breast cancer patients for downstream analysis.
Restructuring and New Leadership
A new management team led by executive chair Jan Groen and chief executive Peter Collins took over in late 2025. The company completed an oversubscribed $10.9 million fundraise, raising more than twice its market value at the time. Headcount was cut by about 60% in 2025 and fell further from 44 to 39 in early 2026, with annual cash operating costs expected to drop by more than £6.6 million.
Revenue Momentum
CelLBxHealth guided to at least £2.1 million of revenue for 2026, supported by contracted revenue and expected sales conversions, and said further opportunities could support an upgrade. It said it was in the final stages of a master services agreement with a top-ten global pharmaceutical company and in advanced talks with one of the largest private US healthcare providers about two clinical studies. First-half results showed second-quarter revenue doubled.
ADC Opportunity
A peer-reviewed article published on 3 August 2026 in The Journal of Liquid Biopsy showed that Parsortix-enriched circulating tumour cells from patients with triple-negative breast cancer and epithelial ovarian cancer expressed antibody-drug conjugate targets including TROP-2, FRα and PD-L1. Antibody-drug conjugates are one of oncology's fastest-growing drug classes, with a market estimated at about $17 billion. Tracking target expression on live tumour cells could help drug developers select patients, which creates a clear commercial use case for LSE:CLBX.
Repeat Pharma Business
CelLBxHealth signed a new statement of work worth about $65,000 with an established US pharmaceutical customer to process around 100 patient samples for mRNA analysis. Executive chair Jan Groen said it demonstrated repeat business opportunities and growing commercial demand.
Share Price and Funding
The shares rose 27% to 1.3p when the company issued its 50% growth guidance and traded around 0.87p on the date of the US pharma contract announcement. The first-half report noted that funding beyond the second quarter of 2027 remains uncertain, so cash runway will be closely watched.
Why Circulating Tumour Cells Matter
Circulating tumour cells are cancer cells that have shed from a tumour into the bloodstream. Analysing them through a simple blood test, known as a liquid biopsy, can give insights into cancer biology without repeated tissue biopsies. Unlike tests that analyse fragments of DNA, intact cells allow researchers to study proteins, RNA and whole-cell characteristics. This is particularly valuable for drug developers who need to know whether a patient's cancer expresses the target a drug attacks. CelLBxHealth has refocused its commercial strategy on product sales through clinical research organisations and laboratory partners, laboratory services from its GCLP-certified UK laboratory, and laboratory-developed tests, building multiple revenue streams around the Parsortix platform. Success in biopharma services can provide recurring, higher-value contracts and validate the technology for broader clinical use, which would strengthen the long-term case for LSE:CLBX.
What Investors Are Watching Next
Investors will look for a third-quarter trading update, confirmation of the top-ten pharma master services agreement, clinical study agreements with the US healthcare provider, progress toward at least £2.1 million of revenue, and the funding plan for 2027.
Risks
Risks include funding, slow adoption, competition in liquid biopsy and dependence on a small number of pharma customers. CelLBxHealth plc (LSE:CLBX) has a credible technology but needs scale.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...